SYNTEX FEMSTAT (BUTOCONAZOLE NITRATE) REDUCED THERAPY TIME
SYNTEX FEMSTAT (BUTOCONAZOLE NITRATE) REDUCED THERAPY TIME is being emphasized by the firm in an announcement of the product's approval. Femstat "is the first three-day cream for the treatment of vaginal yeast infections in non-pregnant patients. In pregnant patients, six-day treatment is recommended . . . In contrast, all other currently available cream therapies must be used for at least seven days," Syntex said in a recent press release. FDA approved Femstat (butoconazole 2% cream) as a 1C antifungal agent, a classification indicating that the drug is a new chemical entity representing little therapeutic gain. A suppository form containing 100 mg butoconazole was also cleared by the agency. The firm said that Femstat is highly effective in treating candidiasis, a common form of vaginitis that can cause itching, unusual discharge and pain during intercourse. Syntex stated that, "unlike suppositories and inserts, ]Femstat[ cream can be applied externally to treat symptoms such as itching and soreness. Femstat's low rate of absorption means it stays mainly on surface tissues at the application site, where most of the infecting fungi are." Syntex said it will begin marketing the new product during the first quarter, and that physicians can start prescribing Femstat in mid-February.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth